Pharmacokinetics and oral bioavailability of pravastatin in dogs
- 1 November 1996
- journal article
- research article
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 143 (2) , 265-269
- https://doi.org/10.1016/s0378-5173(96)04714-x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Influences of Pravastatin and Simvastatin, HMG-CoA Reductase Inhibitors, on Myocardial Stunning in DogsJournal of Cardiovascular Pharmacology, 1993
- Physiological Parameters in Laboratory Animals and HumansPharmaceutical Research, 1993
- Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-onesJournal of Medicinal Chemistry, 1992
- Disposition and metabolism of pravastatin sodium in rats, dogs and monkeysEuropean Journal of Drug Metabolism and Pharmacokinetics, 1992
- PravastatinDrugs, 1991
- Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductaseEuropean Journal of Clinical Pharmacology, 1991
- Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors.Journal of Lipid Research, 1990
- Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.British Journal of Clinical Pharmacology, 1990
- Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometryJournal of Mass Spectrometry, 1989